急性呼吸窘迫综合征住院患者使用阿托伐他汀对临床结局的影响

张凯旋; 姚智远; 廖兆敏; 伍威; 江贵军; 张召才; 宋振举; 詹丽英; 夏文芳

doi:10.14188/j.1671-8852.2024.0519

您当前的位置：

首页 >

文章列表页 >

急性呼吸窘迫综合征住院患者使用阿托伐他汀对临床结局的影响

急性呼吸窘迫综合征专题研究 | 更新时间：2026-11-05

- 急性呼吸窘迫综合征住院患者使用阿托伐他汀对临床结局的影响
- Effect of atorvastatin on clinical outcomes in hospitalized patients with acute respiratory distress syndrome
- 武汉大学学报（医学版） 2025年46卷第2期页码：194-198
- 作者机构：
  
  1.武汉大学人民医院重症医学科湖北武汉 430060
  2.浙江大学医学院附属第二医院重症医学科/浙江省急危重症临床医学研究中心浙江杭州 310009
  3.复旦大学附属中山医院急诊科/复旦大学应急救援与急危重症研究所上海 200032
- 作者简介：
  
  张凯旋，男，1999—，医学硕士生，主要从事ARDS研究，E⁃mail：2023283020119@whu.edu.cn
  夏文芳，女，1981—，医学博士，主任医师，副教授，主要从事脓毒症肺损伤、脓毒症微循环功能障碍与器官功能损伤、危重症脏器功能保护研究，E⁃mail：59267089@qq.com
- 基金信息：
  
  国家重点研发计划项目(2021YFC2501800);国家自然科学基金面上项目(82272226);武汉市知识创新专项项目(2023020201010165);武汉大学人民医院交叉创新人才项目(JCRCZN⁃2022⁃017);武汉大学研究生导师育人方式创新项目(413200144)
- DOI：10.14188/j.1671-8852.2024.0519
  中图分类号： R563.9
- 收稿：2024-07-10，
  
  纸质出版：2025-02-25
- 稿件说明：
移动端阅览
张凯旋,姚智远,廖兆敏等.急性呼吸窘迫综合征住院患者使用阿托伐他汀对临床结局的影响[J].武汉大学学报（医学版）,2025,46(02):194-198.

ZHANG Kaixuan,YAO Zhiyuan,LIAO Zhaomin,et al.Effect of atorvastatin on clinical outcomes in hospitalized patients with acute respiratory distress syndrome[J].Medical Journal of Wuhan University,2025,46(02):194-198.
张凯旋,姚智远,廖兆敏等.急性呼吸窘迫综合征住院患者使用阿托伐他汀对临床结局的影响[J].武汉大学学报（医学版）,2025,46(02):194-198. DOI： 10.14188/j.1671-8852.2024.0519.

ZHANG Kaixuan,YAO Zhiyuan,LIAO Zhaomin,et al.Effect of atorvastatin on clinical outcomes in hospitalized patients with acute respiratory distress syndrome[J].Medical Journal of Wuhan University,2025,46(02):194-198. DOI： 10.14188/j.1671-8852.2024.0519.

摘要

目的

探讨急性呼吸窘迫综合征（ARDS）住院患者使用阿托伐他汀对于炎症指标、凝血功能及预后的影响。

方法

本研究采用回顾性队列研究，在武汉大学人民医院ARDS专病数据库中选取了256名入住ICU并且诊断为ARDS的患者，其中128名使用了阿托伐他汀治疗（阿托伐他汀组），128名未使用（对照组），观察阿托伐他汀用药前后患者炎症指标及凝血功能指标PT和APTT的变化，并且评估使用阿托伐他汀对患者预后的影响。

结果

阿托伐他汀组28 d死亡率与对照组相比显著降低（

0.05），无呼吸机天数和ICU住院时间无显著差异。阿托伐他汀组用药前后炎症指标无明显改善（

0.05）；PT和APTT延长（

0.05）。

结论

ARDS患者使用阿托伐他汀可改善凝血功能，并能降低其死亡率，提示阿托伐他汀可改善ARDS患者的临床结局，可作为ARDS患者的一种治疗选择。

Abstract

Objective

To investigate the impact of atorvastatin on inflammatory markers

coagulation function

and prognosis in hospitalized patients with acute respiratory distress syndrome （ARDS）.

Methods

We conducted a retrospective cohort study using the ARDS⁃specific database from Renmin Hospital of Wuhan University. A total of 256 ICU patients diagnosed with ARDS were selected

inclunding 128 patients who received atorvastatin treatment （atorvastatin group） and 128 did not (control group). Changes in inflammatory markers and coagulation function (PT and APTT) were observed before and after atorvastatin administration and its impact on patient prognosis was assessed.

Results

In the atorvastatin group

the 28⁃day mortality rate was significantly lower than that in the control group (

0.05). However

there was no significant improvement in inflammatory markers after atorvastatin treatment (

0.05); coagulation indices

and APTT

in the atorvastatin group were prolonged after treatment (

0.05).

Conclusion

The use of atorvastatin in ARDS patients can improve coagulation function and reduce mortality rates

suggesting that atorvastatin may improve clinical outcomes and could be considered a therapeutic option for ARDS patients.

关键词

Keywords

references

Matthay M A , Arabi Y , Arroliga A C , et al . A new global definition of acute respiratory distress syndrome [J ] . Am J Respir Crit Care Med , 2024 , 209 ( 1 ): 37 ⁃ 47 .

Villar J . What is the acute respiratory distress syndrome? [J ] . Respir Care , 2011 , 56 ( 10 ): 1539 ⁃ 1545 .

Bellani G , Laffey J G , Pham T , et al . Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries [J ] . JAMA , 2016 , 315 ( 8 ): 788 ⁃ 800 .

Meyer N J , Gattinoni L , Calfee C S . Acute respiratory distress syndrome [J ] . Lancet , 2021 , 398 ( 10300 ): 622 ⁃ 637 .

Schenk P , Spiel A O , Hüttinger F , et al . Can simvastatin reduce COPD exacerbations? A randomised double⁃blind controlled study [J ] . Eur Respir J , 2021 , 58 ( 1 ): 2001798 .

Tong F , Dong B , Chai R K , et al . Simvastatin nanoparticles attenuated intestinal ischemia/reperfusion injury by downregulating BMP4/COX⁃2 pathway in rats [J ] . Int J Nanomedicine , 2017 , 12 : 2477 ⁃ 2488 .

Chen W J , Pan J Y . Anatomical and pathological observation and analysis of SARS and COVID⁃19: Microthrombosis is the main cause of death [J ] . Biol Proced Online , 2021 , 23 ( 1 ): 4 .

Prével R , Dupont A , Labrouche⁃Colomer S , et al . Plasma markers of neutrophil extracellular trap are linked to survival but not to pulmonary embolism in COVID⁃19⁃related ARDS patients [J ] . Front Immunol , 2022 , 13 : 851497 .

Manitsopoulos N , Orfanos S E , Kotanidou A , et al . Inhibition of HMGCoA reductase by simvastatin protects mice from injurious mechanical ventilation [J ] . Respir Res , 2015 , 16 ( 1 ): 24 .

National Heart L , Truwit J D , Bernard G R , et al . Rosuvastatin for sepsis⁃associated acute respiratory distress syndrome [J ] . N Engl J Med , 2014 , 370 ( 23 ): 2191 ⁃ 2200 .

Calfee C S , Delucchi K L , Sinha P , et al . Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: Secondary analysis of a randomised controlled trial [J ] . Lancet Respir Med , 2018 , 6 ( 9 ): 691 ⁃ 698 .

Corsini A , Bellosta S , Baetta R , et al . New insights into the pharmacodynamic and pharmacokinetic properties of statins [J ] . Pharmacol Ther , 1999 , 84 ( 3 ): 413 ⁃ 428 .

Glynn R J , Danielson E , Fonseca F A H , et al . A randomized trial of rosuvastatin in the prevention of venous thromboembolism [J ] . N Engl J Med , 2009 , 360 ( 18 ): 1851 ⁃ 1861 .

Liu C , Shen M C , Tan W L W , et al . Statins improve endothelial function via suppression of epigenetic⁃driven EndMT [J ] . Nat Cardiovasc Res , 2023 , 2 ( 5 ): 467 ⁃ 485 .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

乙酰半胱氨酸在急性呼吸窘迫综合征治疗中的作用

参附注射液联合治疗减轻脓毒症凝血病：一项随机对照研究

高血清镁水平与急性呼吸窘迫综合征患者死亡率的关联性

糖皮质激素对成人急性呼吸窘迫综合征患者预后影响的Meta分析

ICU严重多发伤并发急性呼吸窘迫综合征的危险因素分析